Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PS-341 in Metastatic Renal Cell Cancer
NCT00025376Phase 2Completed
- Sponsor
- University of Chicago
- Start
- Oct 2001
- Primary completion
- Sep 2002
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in renal cell carcinoma (RCC), sponsored by University of Chicago. Started Oct 2001; status: completed.
02
Drugs
bortezomib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00025376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025376.